Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Sionna Therapeutics, Inc.NASDAQ: SION
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns positive
Q1 FY2026 capital expenditures was $0, compared with -$86K a year earlier. Trailing-twelve-month capital expenditures was -$291K. Over 3 fiscal years it compounded at -41.4% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$72.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (377K) USD
- Year-over-year change
- -1296.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (377K) | -1296.3% |
| FY2024 | 2024-12-31 | (27K) | +97.6% |
| FY2023 | 2023-12-31 | (1.12M) | +40.4% |
| FY2022 | 2022-12-31 | (1.87M) | — |
Capital Expenditures vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 capital expenditures of $291K is the smallest of the 11 companies compared; the peer median is $1.09M.
- Its year-over-year change of +238.4% is the 2nd highest of 11, against a peer median of -22.7%.
- Over three fiscal years its annual growth of -41.4% compares with a peer median of -3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $17.42M | -64.1% | -16.2% | 25.7% | |
| LTM Sep 2026 | $9.67M | +36.9% | +239.3% | — | |
| LTM Sep 2026 | $7.48M | +241.6% | +14.1% | 6676.8% | |
| LTM Mar 2026 | $1.3M | +81.3% | +9.9% | 0.4% | |
| LTM Mar 2026 | $1.24M | +4.2% | +200.5% | 0.3% | |
| LTM Mar 2026 | $945K | +77.3% | -45.5% | 4.4% | |
| LTM Sep 2026 | $858.9K | -55.9% | -51.2% | 0.3% | |
| LTM Mar 2026 | $588K | -49.6% | -26.1% | 2.9% | |
| LTM Jun 2026 | $475K | -64.9% | -74.1% | — | |
| LTM Jun 2026 | $408K | -68.1% | +116.6% | — | |
| LTM Mar 2026 | $291K | +238.4% | -41.4% | — | |
| Peer median (excluding SION) | $1.09M | -22.7% | -3.1% | 2.9% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.